O'NEIL PRESUEL: Open Payments
NPI 1184370934 · COLTON, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,278 in 145 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $1,260 · 2025 $3,278
Food & beverage: $3,278
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 38 | $1,135 |
| Teva Pharmaceuticals USA, Inc. | 25 | $460 |
| Vanda Pharmaceuticals Inc. | 18 | $442 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $266 |
| Otsuka America Pharmaceutical, Inc. | 11 | $222 |
| Alkermes, Inc. | 10 | $186 |
| Lundbeck LLC | 9 | $167 |
| Janssen Pharmaceuticals, Inc | 6 | $136 |
| Supernus Pharmaceuticals, Inc. | 4 | $98 |
| Noven Therapeutics, LLC | 4 | $70 |
Products named: INGREZZA, REXULTI, AUSTEDO XR, CAPLYTA, FANAPT, HETLIOZ, UZEDY, ARISTADA.
Industry payments across CA — which companies pay providers there.
